QT Imaging Announces Second Blinded Screening Trial Finding Its Technology Similarly Effective as Digital Breast Tomosynthesis
Retrieved on:
화요일, 4월 16, 2024
Research, Medical Devices, Women, Clinical Trials, Biotechnology, Radiology, Consumer, Health, Science, Oncology, FDA, University, ROC, Cancer, Woman, Breast cancer, Breast disease, Tomosynthesis, MD, 3D, DBT, QTI, Patient, MRMC, AUC, Recall, Medical imaging
The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.
Key Points:
- The study found that QTI’s Breast Acoustic CTTM is similarly effective as digital breast tomosynthesis (DBT), also known as 3D mammography, in that the area under receiver operating characteristic curve (AUC) was statistically non-inferior for QTI scan compared with DBT for the AUC difference margin of -0.05.
- This means that QTI technology is non-inferior to DBT in the detection of breast lesions as a whole, with high specificity in determining benign cysts and thus decreasing benign recall rates.
- Unfortunately, routine screening mammograms are not recommended for women under 40 because risks outweigh potential benefits at this young age.
- Fortunately, the now published results suggest that QTI’s technology can be a much-needed potential alternative to mammography for women too young to undergo mammography screening.